Introduction:
Paragon Bioservices (Paragon) announces the expansion of a new process development and cGMP manufacturing facility located near Baltimore/Washington International Thurgood Marshall (BWI) Airport.
Features:
The company is planning to include commercial manufacturing capabilities in 18 to 24 months.
Facilities including mammalian, microbial and virus suites, as well as automated aseptic fill-finish capabilities, will also be expanded in the cGMP manufacturing facility to encompass an additional 10, 000 square-feet of space within the BioPark.
Paragon’s new planned 150,000 square-foot facility continues to increase growth which includes several 500L and 2000L single-use bioreactors for clinical trial and eventually commercial material production, as well as additional research laboratory space for process optimisation and scale up.
The new facility will meet the terms with both European Medicines Agency (EMA) and U.S. Food and Drug Administration FDA manufacturing requirements for biopharmaceutical manufacturing.
As part of the expansion of the new facility, over 200 new jobs will be created to continue its manufacturing operations.
With this, the facility will take gene therapy to the next level and the company estimates that it will hire more than 200 employees for the new facility over the next three years.
The expansion is part of Paragon’s current world-class client base requesting additional pre-clinical and commercial capacity.
Specifications:
| Name | Paragon Bioservices (Paragon) |
| Location | Baltimore, USA |
| Type | Expansion |
| Parties Involved | Paragon Bioservices (Paragon) |
